Lumipulse® G pTau 217 CSF Assay
Alzheimer's Disease (Tau Pathology)
Research Use OnlyLaunched (Jan 2026)
Key Facts
Indication
Alzheimer's Disease (Tau Pathology)
Phase
Research Use Only
Status
Launched (Jan 2026)
Company
About fujirebio-diagnostics
Fujirebio Diagnostics is an R&D-driven innovator and global provider of in vitro diagnostic solutions, with a mission to create new value in healthcare. Its core achievement is pioneering blood-based biomarkers for Alzheimer's disease, including the first FDA-cleared blood test for amyloid pathology. The company's strategy leverages its proprietary Lumipulse® G platform for internal assay development while operating a synergistic CDMO business, reinvesting partnership revenues to fuel a robust pipeline in neurology, oncology, and infectious diseases.
View full company profile